Introduction
============

Obesity is a chronic low-grade inflammatory state, which is characterized by an increase in circulating inflammatory factors partly due to changes in cytokine and adipokine production in adipose tissue (AT).^[@bib1]^ In addition to mature adipocytes, AT is composed of different cell types in the stromavascular fraction^[@bib1]^ that may have different roles in obesity-related inflammation of AT. It has been suggested that a proinflammatory state with a concomitant upregulation of inflammation-related genes might lead to changes in the expression of genes linked to the extracellular matrix (ECM) in order to accommodate the growing AT.^[@bib2]^ Weight reduction (WR) is an effective way to reverse the state of inflammation and decrease biological markers of inflammation in the circulation, and also the expression of inflammatory markers in AT.^[@bib3]^

Genome-wide transcriptomics analysis performed from AT of the subjects with metabolic syndrome (MetS) participating in the Genobin study^[@bib4]^ showed that the ECM-associated gene, *microfibrillar-associated protein 5* (*MFAP5*),^[@bib5]^ also known as *MAGP2*, was one of the genes, whose expression was downregulated in subcutaneous AT along with WR and improved insulin sensitivity. It was found that *MFAP5* mRNA was highly expressed in AT, although its function in human AT is not known. In this work, our aim was to investigate whether the change of *MFAP5* gene expression, along with WR, is correlated with the measures of glucose metabolism and body adiposity in the Genobin study individuals and with circulating adipokines and expression of genes, which were changed after WR.

Materials and methods
=====================

Altogether 75 overweight/obese (body mass index (BMI) 28--40 kg m^−2^) subjects aged 40--70 years were recruited into the Genobin study (NTC00621205) described in detail earlier.^[@bib4]^ The subjects had impaired fasting glucose or impaired glucose tolerance, and at least two other features of the MetS.^[@bib6]^ Subjects were randomly assigned to one of the following groups: WR (*n*=28), aerobic exercise training (*n*=15), resistance exercise training (*n*=14) or control group (*n*=18),^[@bib4]^ but in this study only the data from the WR and control groups were included and analyzed. The number of study participants varied among the correlation analyses due to missing values of the variables in some of the participants. In addition, mRNA samples were not available from all the participants. The final number of participants included in the data analysis is indicated in the table footnote. Subjects were matched for age, gender, BMI and the status of glucose metabolism. Briefly, the WR group had an intensive WR period lasting for 12 weeks during which the study subjects followed detailed instructions given by a clinical nutritionist. These instructions were based on a 4-day dietary record and an interview. Between weeks 12 and 33, the aim was to maintain the achieved reduction in weight. The control group was asked not to change their lifestyle habits. The intervention was performed in accordance with the standards of the Declaration of Helsinki. The Ethics Committee of the district hospital region of Northern Savo and Kuopio University Hospital approved the study plan. All participants gave a written informed consent.

Glucose metabolism was measured using an oral glucose tolerance test and by frequently sampled intravenous glucose tolerance test, according to the Minimal Model method,^[@bib7]^ at baseline and at the end of the intervention.^[@bib4]^ Insulin sensitivity index, glucose effectiveness and acute phase insulin response to glucose were calculated by the MINMOD Millenium software.^[@bib8]^

After an overnight fast, AT samples were taken by needle biopsy from subcutaneous abdominal AT, before and after the intervention under local anesthesia (10 mg ml^−1^ lidocaine) to collect 0.5--5 g of AT for the mRNA expression studies. AT samples were washed twice with phosphate-buffered saline and treated with RNAlater according to the instructions provided by the manufacturer (Ambion, Austin, TX, USA), and stored in −80 °C, until used for RNA extraction. RNA extraction, cDNA synthesis and quantitative real-time PCR (QPCR) were performed as previously described in detail.^[@bib4]^ Briefly, TRIzol method followed by purification with RNeasy Mini Kit (Invitrogen, Carlsbad, CA, USA and Qiagen, Valencia, CA, USA) were used for extracting total RNA according to the manufacturer\'s instructions. Nanodrop (NanoDrop Technologies, Wilmington, DE, USA) was used for measuring the RNA concentration and the A260/A280 ratio. RNA was reverse-transcribed into cDNA using High-capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) according to the instructions provided by the manufacturer. QPCR with TaqMan chemistry (Applied Biosystems) by using ABI Prism 7500 analyzer (Applied Biosystems) was used for the confirmation of microarray gene expression results. The analysis for the relative quantity of a specific gene, before and after the intervention in AT, was performed as described previously.^[@bib4]^ Expression of target genes were normalized to *cyclophilin A1 (PPIA)* expression.

The clinical data were analyzed using the SPSS software for Windows version 14.0 (SPSS Inc., Chicago, IL, USA). Data are given as mean±s.d., unless otherwise indicated. The normality of distributions of the variables was tested with the Kolmogorov--Smirnov test, with Lilliefors significance correction. Logarithmic transformation was used to achieve normal distribution, whenever needed (indicated in tables and/or figures). General linear model for univariate analysis was used to test the difference in fold-change values of mRNA expression between the groups. Paired samples *t*-test was used for comparing the baseline and endpoint measurements within the study group. Correlation analyses were carried out using Pearson\'s method. Partial correlation analysis with adjustment for weight at baseline and gender was used when appropriate. The WR and control groups were combined in the correlation analysis at baseline and when studying the correlations of change values. At baseline, this was carried out because the participants who were randomized either to an intervention or a control group represents the same risk population, all having MetS. Thus, the participants were homogenous regarding the selection criteria. After the intervention, the two treatment groups were analyzed separately because of potential treatment effect. Moreover, the correlations between the change of *MFAP5* mRNA expression and the changes of clinical and biochemical measures were studied when the WR and control groups were combined, but also separately, for both the groups. For the clinical and biochemical measurements, *P*\<0.05 was considered as statistically significant.

Results
=======

Values for body weight, fasting plasma glucose and serum insulin concentration were at baseline 92.1±14.9 kg, 6.2±0.4 mmol l^−1^ and 11.5±5.4 pmol l^−1^, and at the end of the intervention 88.7±14.0 kg, 5.9±0.3 mmol l^−1^ and 10.7±7.0 pmol l^−1^ for the WR group, respectively. The respective values for the control group were 87.3±8.3 kg, 6.4±0.6 mmol l^−1^ and 9.9±5.0 pmol l^−1^ at baseline and 87.7±9.0 kg, 6.1±0.6 mmol l^−1^ and 10.6±6.0 pmol l^−1^ at the end of the intervention, respectively.

The QPCR analysis for *MFAP5* expression confirmed the data obtained by microarray ([Figure 1](#fig1){ref-type="fig"}). When the comparisons were made within the groups, the mRNA expression levels of *MFAP5* showed significant decrease (94.2±49.0 to 81.7±41.7 AU, *P*=0.017) in the WR group and no change was seen in the control group (106.4±40.4 to 109.4±34.5 AU, *P*=0.636). Similar results were also obtained by microarray showing that *MFAP5* expression was significantly downregulated in the WR group (*P*=0.004).^[@bib4]^ Fold-change results by QPCR showed a significant reduction in *MFAP5* mRNA expression in the WR group (*P*=0.028) when compared with the control group.

Correlation analyses were performed with the combined study groups at baseline. *MFAP5* mRNA expression correlated significantly at baseline with BMI ([Table 1](#tbl1){ref-type="table"}). Moreover, the expression of *MFAP5* correlated significantly with fasting serum insulin concentration at baseline, when adjusted for baseline body weight ([Table 1](#tbl1){ref-type="table"}). There was no correlation between *MFAP5* mRNA expression and fasting plasma glucose levels.

Interestingly, at baseline, the mRNA expression of *MFAP5* correlated negatively with fasting serum adiponectin and positively with leptin concentrations. Moreover, a positive correlation was also found for fasting plasma interleukin (IL)-1Ra and a negative one for fasting plasma IL-1β concentrations, when adjusted for baseline body weight ([Table 1](#tbl1){ref-type="table"}). *MFAP5* mRNA expression correlated positively with leptin gene expression ([Table 1](#tbl1){ref-type="table"}) at baseline (adjusted for baseline body weight) and with adiponectin and IL-6 expression after the WR ([Table 1](#tbl1){ref-type="table"}). However, at the expression level, there was no correlation with cytokines like transforming growth factor beta 1, tumour necrosis factor alpha, IL-1β or IL-1Ra ([Table 1](#tbl1){ref-type="table"}).

Taken into account that MFAP5 is involved in the NOTCH pathway,^[@bib9]^ we studied the correlation of *MFAP5* mRNA expression with *NOTCH1* and *NOTCH2* mRNA expressions. *MFAP5* mRNA expression did not correlate with the expressions of these genes.

We also studied whether *MFAP5* mRNA expression is correlated with expressions of genes, which are involved in modulation of AT formation. *MFAP5* expression correlated positively with *peroxisome proliferator-activated receptor gamma (PPARγ)*, *cyclin D2 (CCND2)* and *a disintegrin and metalloproteinase domain 12 (ADAM12)* mRNA expressions at baseline (adjusted for baseline body weight), as well as after the WR ([Table 1](#tbl1){ref-type="table"}), when adjusted for the corresponding body weight.

The change in *MFAP5* mRNA expression level correlated significantly with the change IN body fat mass (*r*=0.392, *P*=0.009). Furthermore, the change of *MFAP5* expression level correlated significantly with the changes of *ADAM12*, *adiponectin (ADIPOQ)* and *NOTCH2* expression levels (*r*=0.343, *P*=0.026; *r*=0.433, *P*=0.004; *r*=0.438, *P*=0.006), respectively, when adjusted for the change of body weight and the WR and control groups were combined. When the groups were analyzed separately, there was also a significant correlation in the WR group between the change of *MFAP5* mRNA expression and the change of *ADIPOQ* mRNA expression. In the control group, there were no significant correlations.

Discussion
==========

MFAP5 is associated with microfibrils in elastin networks in a number of tissues, and its function may be related to cell signaling during microfibril assembly, elastogenesis and cell survival.^[@bib5],\ [@bib10],\ [@bib11]^ It has been shown that MFAP5 promotes angiogenesis and interacts with NOTCH1 by either activating or suppressing its activity, depending on the cell type involved.^[@bib9],\ [@bib12]^ Furthermore, MFAP5 is increased in fibrotic skin of humans and in mouse models with systemic sclerosis.^[@bib13]^ Whether its function in AT is similar to previous findings is not known.

ECM is composed of structural and multifunctional molecules such as collagen, adhesive glycoproteins and proteoglycans.^[@bib14],\ [@bib15]^ In AT, ECM maintains the structural integrity of adipocytes, and has an important role in AT formation.^[@bib15]^ Development of obesity induces changes in AT (e.g., adipocyte hypertrophy, new adipocyte formation), which are associated with remodeling of ECM proteins and angiogenesis.^[@bib14],\ [@bib15],\ [@bib16]^ Genes related to ECM and cytoskeleton have been shown to be upregulated by high-fat diet and correlated with body weight in mice.^[@bib14],\ [@bib17]^ Not only weight gain induces ECM remodeling but also weight loss modifies the expression of ECM molecules.^[@bib15]^ The chronic proinflammatory state in obesity is suggested to be associated with ECM remodeling and subsequent interstitial fibrosis. It has also been shown that human preadipocytes secrete fibrotic factors because of inflammatory stimulus.^[@bib18]^

Recent human and rodent studies have demonstrated that collagen VI is highly expressed in obese state and is associated with increased BMI, adipose fat mass and inflammation. There is also evidence that a loss of collagen VI in AT leads to improvements of metabolic profile.^[@bib19],\ [@bib20],\ [@bib21]^ Expression changes in microfibrillar proteins such as MFAP5, is known to participate in collagen synthesis and accumulation.^[@bib22]^ Lemaire *et al.*^[@bib23]^ have demonstrated that MFAP5 could enhance type I collagen matrix by stabilizing type I procollagen. Furthermore, it has been shown that MAGP-1, which is structurally related molecule to MFAP5, could bind to type VI collagen. It could also be possible that MFAP5 might bind to collagen VI or other ECM molecules of AT, but only fibrillin 1 has been shown to interact with MFAP5.^[@bib23]^

Our results showed that *MFAP5* expression was correlated with the change of body fat mass, fasting serum adiponectin and leptin. Reduced adiponectin levels and increased leptin levels are associated with obesity and insulin resistance.^[@bib24]^ Moreover, adiponectin and leptin are involved in obesity-related angiogenesis and ECM remodeling.^[@bib16],\ [@bib24]^ Therefore, the found correlation between the *MFAP5* gene expression and adiponectin and leptin might be related to angiogenesis and ECM remodeling during development of obesity and reduction of body fat mass along with WR.

In addition to MFAP5, also specific ADAM isoforms are shown to be involved in NOTCH pathway. Moreover, ADAM12, *CCND2*, NOTCH receptors and PPARγ are known to be involved in the development of AT, differentiation and adipogenesis.^[@bib25],\ [@bib26],\ [@bib27]^ Interestingly, our results showed a correlation between *MFAP5* mRNA expression and *PPARγ*, *CCND2* and *ADAM12* mRNA expressions at baseline and after the intervention, as well as with the changes of *ADAM12*, *ADIPOQ* and *NOTCH2* gene expressions. It is possible that the effect of *MFAP5* on angiogenesis or the role of *MFAP5* gene in AT remodeling is mediated via factors related to adipogenesis and differentiation. It could also be possible that *MFAP5* is a 'structure\' gene and an 'innocent bystander\' that will respond along with other ECM proteins to state of obesity and adipokines secreted by AT. Further studies are necessary to determine which mechanisms might be involved in the regulation of *MFAP5* expression in adipocytes.

In conclusion, *MFAP5* is highly expressed in AT and is correlated with markers of insulin resistance. It is possible that MFAP5 is involved in ECM remodeling, which enables AT enlargement in obesity. This process seems to be reversible, at least partly, along with WR.
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###### Correlations of *MFAP5* mRNA expression in subcutaneous adipose tissue with anthropometric, biochemical measures, and with selected genes expressed in subcutaneous adipose tissue before and after the intervention in weight reduction and control groups; adjusted for body weight

                                                            *Groups combined (*n*=46)*   *Weight reduction group (*n*=28)*   *Control group (*n*=18)*                               
  -------------------------------------------------------- ---------------------------- ----------------------------------- -------------------------- ----------- ---------------- -----------
  *Anthropometric and biochemical measures*                                                                                                                                         
   Body mass index (kg m^−2^)[b](#t1-fn3){ref-type="fn"}       **0.369^\#\#\#\#^**                   **0.014**                       0.068°°              0.737         0.128          0.613
   Body weight (kg)[b](#t1-fn3){ref-type="fn"}                    0.043^\#\#\#^                        0.785                         −0.213°              0.297       −0.122 ^×^       0.641
   Body fat mass (kg)[b](#t1-fn3){ref-type="fn"}                 0.277^\#\#\#\#^                       0.069                         0.052°°              0.798         0.114          0.653
   Waist circumference (cm)                                       0.282^\#\#\#^                        0.071                        **0.431**°          **0.032**     −0.011 ^×^       0.968
   S~I~ ((mU l^−1^)^−1^ × min^−1^)                                 −0.260^\#\#^                        0.101                         −0.162°              0.439     **−0.429** ^×^   **0.017**
   fS-adiponectin (μg ml^−1^)                                   **−0.378**^\#\#\#^                   **0.014**                       −0.369°°             0.063     **−0.626** ^×^   **0.009**
   fS-leptin (ng ml^−1^)                                        **0.361**^\#\#\#^                    **0.019**                        0.155°              0.459       0.153 ^×^        0.571
   fS-insulin (pmol l^−1^)                                       **0.397^\#\#^**                     **0.010**                        0.165°              0.429       0.352 ^×^        0.181
   fP-glucose (mmol l^−1^)                                         0.132^\#\#^                         0.41                          −0.093°              0.66        0.358 ^×^        0.174
   fS-TNFα (pg ml^−1^)                                            −0.162^\#\#\#^                       0.305                         −0.296°              0.151       0.028 ^×^        0.919
   fP-IL1β (pg ml^−1^)                                          **−0.401**^\#\#\#^                   **0.009**                        −0.22°              0.29        -0.207 ^×^       0.441
   fP-IL1Ra (pg ml^−1^)                                         **0.347**^\#\#\#^                    **0.024**                        0.325°              0.113       0.469 ^×^        0.067
   hsCRP (mg l^−1^)                                               -0.021^\#\#\#^                       0.895                         -0.106°              0.615       -0.076 ^×^       0.781
                                                                                                                                                                                          
  *Gene expression in adipose tissue (AU)*                                                                                                                                          
   Leptin                                                       **0.338**^\#\#\#^                    **0.028**                        0.259°              0.211       0.357 ^×^        0.174
   Adiponectin                                                    0.033^\#\#\#^                        0.838                        **0.488**°          **0.013**     0.011 ^×^        0.968
   PPAR-γ                                                       **0.511**^\#\#\#^                    **0.001**                      **0.621**°          **0.001**     0.195 ^×^        0.469
   TNF-α                                                          0.132^\#\#\#^                        0.404                          0.018°              0.932        0.39 ^×^        0.136
   IL1-β                                                           0.071^\#\#^                         0.659                        0.140^\*^             0.524        0.09 ^×^        0.741
   IL-1Ra                                                         0.106^\#\#\#^                        0.504                        0.054^\*^             0.807       0.386 ^×^        0.14
   IL-6                                                           0.007^\#\#\#^                        0.966                        **0.409**°          **0.042**     −0.267 ^×^       0.317
   TGF-β1                                                            0.25^\#^                          0.12                         0.388^\*^             0.067       0.089 ^×^        0.743
   NOTCH1                                                           −0.277^\#^                         0.083                        −0.191^\*^            0.383       −0.121 ^×^       0.656
   NOTCH2                                                           0.191^\#^                          0.239                        0.324^\*^             0.131        0.37 ^×^        0.158
   CCND2                                                        **0.523**^\#\#\#^                   **\<0.001**                     **0.401**°          **0.047**     0.392 ^×^        0.133
   ADAM22                                                         0.248^\#\#\#^                        0.114                        0.261^\*^             0.229       0.473 ^×^        0.064
   ADAM12                                                       **0.584**^\#\#\#^                   **\<0.001**                     **0.552**°          **0.004**   **0.579** ^×^    **0.019**

Abbreviations: ADAM12, A disintegrin and metalloproteinase domain 12; ADAM22, A disintegrin and metalloproteinase domain 22; AU, arbitrary unit; CCND2, cyclin D2; fP, fasting plasma; fS, fasting serum; hsCRP, high-sensitivity C reactive protein; IL-6, interleukin 6; IL-1Ra, interleukin 1 receptor antagonist; IL-1β, interleukin 1 beta; NOTCH1, notch1 preproprotein; NOTCH2, notch2 preproprotein; PPARγ, peroxisome proliferator-activated receptor gamma; S~I~, insulin sensitivity index; TGF-β1, transforming growth factor beta 1; TNF-α, tumour necrosis factor alpha.

Adjusted for body weight (kg).

Correlation analyses were carried out using Pearson\'s method, no adjustments; ^\#^*n*=41; ^\#\#^*n*=42; ^\#\#\#^*n*=43; ^\#\#\#\#^*n*=44; ^\*^*n*=24; °*n*=26; °°*n*=27; ^×^*n*=17.

Values are logarithmized, when appropriate.

Bold font: result statistically significant (*P*\<0.05).
